Australia markets open in 5 hours 43 minutes

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.3000-0.0500 (-2.13%)
As of 02:17PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 490.64M
Enterprise value 194.70M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.40k
Price/book (mrq)1.06
Enterprise value/revenue 2.24k
Enterprise value/EBITDA -1.04

Trading information

Stock price history

Beta (5Y monthly) 0.86
52-week change 3-51.14%
S&P500 52-week change 323.76%
52-week high 36.0500
52-week low 32.2300
50-day moving average 32.9524
200-day moving average 33.4063

Share statistics

Avg vol (3-month) 32.29M
Avg vol (10-day) 32.63M
Shares outstanding 5208.78M
Implied shares outstanding 6208.78M
Float 8124.55M
% held by insiders 117.55%
% held by institutions 164.58%
Shares short (15 May 2024) 436.43M
Short ratio (15 May 2024) 417.15
Short % of float (15 May 2024) 433.03%
Short % of shares outstanding (15 May 2024) 421.32%
Shares short (prior month 15 Apr 2024) 431.36M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)-315,927.27%

Management effectiveness

Return on assets (ttm)-26.71%
Return on equity (ttm)-55.48%

Income statement

Revenue (ttm)87k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-26.70%
Gross profit (ttm)N/A
EBITDA -270.66M
Net income avi to common (ttm)-292.3M
Diluted EPS (ttm)-1.7800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)384.86M
Total cash per share (mrq)2.25
Total debt (mrq)95.85M
Total debt/equity (mrq)20.77%
Current ratio (mrq)12.80
Book value per share (mrq)2.71

Cash flow statement

Operating cash flow (ttm)-226.99M
Levered free cash flow (ttm)-134.9M